Post-earnings recap
Reported
Mon, May 9, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Amicus Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in the stock price. The lack of revenue data and guidance may leave investors uncertain about the company's future performance. The stock's modest drop of 0.64% reflects cautious sentiment in the market following these results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | -23.46% |
| Revenue | — | N/A | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.